These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 24939497)

  • 1. Linaclotide: a novel agent for chronic constipation and irritable bowel syndrome.
    Love BL; Johnson A; Smith LS
    Am J Health Syst Pharm; 2014 Jul; 71(13):1081-91. PubMed ID: 24939497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of linaclotide in patients with irritable bowel syndrome with constipation or chronic constipation: a meta-analysis.
    Videlock EJ; Cheng V; Cremonini F
    Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1084-1092.e3; quiz e68. PubMed ID: 23644388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacological and clinical profile of linaclotide (Linzess
    Keto Y; Kosako M
    Nihon Yakurigaku Zasshi; 2019; 153(6):289-298. PubMed ID: 31178535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Linaclotide in irritable bowel syndrome with constipation: A Phase 3 randomized trial in China and other regions.
    Yang Y; Fang J; Guo X; Dai N; Shen X; Yang Y; Sun J; Bhandari BR; Reasner DS; Cronin JA; Currie MG; Johnston JM; Zeng P; Montreewasuwat N; Chen GZ; Lim S
    J Gastroenterol Hepatol; 2018 May; 33(5):980-989. PubMed ID: 29319191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety.
    Chey WD; Lembo AJ; Lavins BJ; Shiff SJ; Kurtz CB; Currie MG; MacDougall JE; Jia XD; Shao JZ; Fitch DA; Baird MJ; Schneier HA; Johnston JM
    Am J Gastroenterol; 2012 Nov; 107(11):1702-12. PubMed ID: 22986437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation.
    Rao S; Lembo AJ; Shiff SJ; Lavins BJ; Currie MG; Jia XD; Shi K; MacDougall JE; Shao JZ; Eng P; Fox SM; Schneier HA; Kurtz CB; Johnston JM
    Am J Gastroenterol; 2012 Nov; 107(11):1714-24; quiz p.1725. PubMed ID: 22986440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and tolerability of linaclotide for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation: pooled Phase 3 analysis.
    Nee JW; Johnston JM; Shea EP; Walls CE; Tripp K; Shiff S; Fox SM; Bochenek W; Weissman D; Currie MG; Lembo AJ
    Expert Rev Gastroenterol Hepatol; 2019 Apr; 13(4):397-406. PubMed ID: 30791771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Tolerability of Guanylate Cyclase-C Agonists for Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation: A Systematic Review and Meta-Analysis.
    Shah ED; Kim HM; Schoenfeld P
    Am J Gastroenterol; 2018 Mar; 113(3):329-338. PubMed ID: 29380823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review article: Linaclotide for the management of irritable bowel syndrome with constipation.
    Layer P; Stanghellini V
    Aliment Pharmacol Ther; 2014 Feb; 39(4):371-84. PubMed ID: 24433216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review of the clinical efficacy of linaclotide in irritable bowel syndrome with constipation.
    Johnston JM; Shiff SJ; Quigley EM
    Curr Med Res Opin; 2013 Feb; 29(2):149-60. PubMed ID: 23198977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of linaclotide on severe abdominal symptoms in patients with irritable bowel syndrome with constipation.
    Rao SS; Quigley EM; Shiff SJ; Lavins BJ; Kurtz CB; MacDougall JE; Currie MG; Johnston JM
    Clin Gastroenterol Hepatol; 2014 Apr; 12(4):616-23. PubMed ID: 24075889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized Trial of 2 Delayed-Release Formulations of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation.
    Chey WD; Sayuk GS; Bartolini W; Reasner DS; Fox SM; Bochenek W; Boinpally R; Shea E; Tripp K; Borgstein N
    Am J Gastroenterol; 2021 Feb; 116(2):354-361. PubMed ID: 33065589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Linaclotide, novel therapy for the treatment of chronic idiopathic constipation and constipation-predominant irritable bowel syndrome.
    Vazquez-Roque MI; Bouras EP
    Adv Ther; 2013 Mar; 30(3):203-11. PubMed ID: 23436110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3',5'-monophosphate.
    Castro J; Harrington AM; Hughes PA; Martin CM; Ge P; Shea CM; Jin H; Jacobson S; Hannig G; Mann E; Cohen MB; MacDougall JE; Lavins BJ; Kurtz CB; Silos-Santiago I; Johnston JM; Currie MG; Blackshaw LA; Brierley SM
    Gastroenterology; 2013 Dec; 145(6):1334-46.e1-11. PubMed ID: 23958540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome.
    Andresen V; Camilleri M; Busciglio IA; Grudell A; Burton D; McKinzie S; Foxx-Orenstein A; Kurtz CB; Sharma V; Johnston JM; Currie MG; Zinsmeister AR
    Gastroenterology; 2007 Sep; 133(3):761-8. PubMed ID: 17854590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Linaclotide: a review of its use in the treatment of irritable bowel syndrome with constipation.
    McCormack PL
    Drugs; 2014 Jan; 74(1):53-60. PubMed ID: 24293117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Linaclotide: a novel compound for the treatment of irritable bowel syndrome with constipation.
    Rothstein RD; Friedenberg FK
    Expert Opin Pharmacother; 2013 Oct; 14(15):2125-32. PubMed ID: 24007408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determining an optimal dose of linaclotide for use in Japanese patients with irritable bowel syndrome with constipation: A phase II randomized, double-blind, placebo-controlled study.
    Fukudo S; Nakajima A; Fujiyama Y; Kosako M; Nakagawa A; Akiho H; Nakashima Y; Johnston JM; Miwa H
    Neurogastroenterol Motil; 2018 May; 30(5):e13275. PubMed ID: 29278278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing the Use of Linaclotide in Patients with Constipation-Predominant Irritable Bowel Syndrome: An Expert Consensus Report.
    Rey E; Mearin F; Alcedo J; Ciriza C; Delgado-Aros S; Freitas T; Mascarenhas M; Mínguez M; Santos J; Serra J
    Adv Ther; 2017 Mar; 34(3):587-598. PubMed ID: 28083815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomised clinical trials: linaclotide phase 3 studies in IBS-C - a prespecified further analysis based on European Medicines Agency-specified endpoints.
    Quigley EM; Tack J; Chey WD; Rao SS; Fortea J; Falques M; Diaz C; Shiff SJ; Currie MG; Johnston JM
    Aliment Pharmacol Ther; 2013 Jan; 37(1):49-61. PubMed ID: 23116208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.